Medical Condition News

RSS

Researchers unveil protection mechanism of telomeres from DNA repair

In the latest issue of the journal Nature, Miguel Godinho Ferreira, Principal Investigator at the Instituto Gulbenkian de Ciência (IGC) in Portugal, lead a team of researchers to shed light on a paradox that has puzzled biologists since the discovery of telomeres, the protective tips of chromosomes: while broken chromosome ends generated by DNA damage (such as radiation or cigarette smoke) are quickly joined together, telomeres are never tied to each other, thus allowing for the correct segregation of the genetic material into all cells in our body.

9 Sep 2010

Non-invasive test using patient's breath can detect cancer

A test using a patient's breath could be developed to detect lung, breast, bowel and prostate cancers, a team of scientists have discovered.While these results are only preliminary, the study published in the British Journal of Cancer today (Wednesday), found that sensors could distinguish between the breath of healthy patients and those who have cancer.

9 Sep 2010

Researchers demonstrate how insulin prepares cells for glucose uptake

Using high-resolution microscopy, researchers at the National Institutes of Health have shown how insulin prompts fat cells to take in glucose in a rat model. The findings were reported in the Sept. 8 issue of the journal Cell Metabolism.

9 Sep 2010

Study finds long-term use of bone-strengthening drugs increase risk of oesophageal cancer

People who take bone-strengthening pills called bisphosphonates over a long period of time could be more likely to develop cancer of the oesophagus (gullet), new research suggests.

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

Researchers discover low levels of DHA associated with chronic neurodegenerative disease

UC Irvine researchers have discovered that markedly depleted amounts of an omega-3 fatty acid in brain tissue samples from Alzheimer's patients may be due to the liver's inability to produce the complex fat, also contained in fish-oil supplements.Low levels of docosahexaenoic acid, or DHA, have been associated with the chronic neurodegenerative disease affecting millions of Americans, but no cause had been identified.

9 Sep 2010

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Competitive Technologies, Inc. announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment

9 Sep 2010

Scientists discover natural mechanism to discard amyloid protein

Chemists at the University of California, San Diego, have identified how a protein that accumulates in the brains of people with Alzheimer's disease interferes with the ability of cells to get rid of debris. They also found a natural mechanism by which this protein, amyloid beta, itself may be discarded.

9 Sep 2010

NIH awards second $8 million grant for research into health effects of botanical estrogens

An ongoing research initiative into the health effects of botanical estrogens will get an $8 million boost from the National Institutes of Health.

9 Sep 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma, Inc. will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.

9 Sep 2010

AERI merges with AHEADD to support communities impacted by Autism Spectrum Disorder

The Autism Education and Research Institute (AERI), an organization committed to providing consultative services that incorporates innovative current research in the field of autism, announces their merging with Achieving in Higher Education with Autism / Developmental Disabilities (AHEADD) in order to support consumers, families, schools, and their surrounding communities who are impacted by Autism Spectrum Disorders (ASD).

9 Sep 2010

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

EDAP TMS SA, the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU.

9 Sep 2010

Irregular body weight increases mortality risk in women with colon cancer: Study

Postmenopausal women diagnosed with colon cancer may be at increased risk of death if they fail to maintain a healthy body weight before cancer diagnosis, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

9 Sep 2010

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease (AD).

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by GE Healthcare, in the field of brain imaging.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

Medical Condition News

Researchers unveil protection mechanism of telomeres from DNA repair

Non-invasive test using patient's breath can detect cancer

Researchers demonstrate how insulin prepares cells for glucose uptake

Study finds long-term use of bone-strengthening drugs increase risk of oesophageal cancer

Micro-RNAs programmed cells can lead to malignant growth

Researchers discover low levels of DHA associated with chronic neurodegenerative disease

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Scientists discover natural mechanism to discard amyloid protein

NIH awards second $8 million grant for research into health effects of botanical estrogens

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

AERI merges with AHEADD to support communities impacted by Autism Spectrum Disorder

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

Irregular body weight increases mortality risk in women with colon cancer: Study

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News